In this segment from Thursday's episode, health-care analyst David Williamson takes a look at the third-quarter earnings report from Vivus(NASDAQ:VVUS). Shares fell more than 12% on the news that the company's revenue from its drug Qsymia was nowhere near what investors were hoping for. While the company showed 35% quarter-to-quarter growth, this, too, fell drastically short of the exponential growth investors were hoping for from a pharmaceutical company with a potentially blockbuster new drug rollout. David looks closely into Vivus' prospects, and lists a few other headwinds investors should be aware of.

Author

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid